Price: quote on request. Your total cost is quoted in writing per case.
We give you a written timeline estimate for your case before you commit.
Ask about treatment

Chronic myeloid leukemia (CML): US-approved treatments and how families in the Gulf can access them

A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Chronic myeloid leukemia (CML): the short answer

The US FDA has approved two medicines covered on this page for chronic myeloid leukemia (CML), each for a specific group of patients: Scemblix and Imkeldi. On 17 October 2026, one of them was on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.

  • US FDA-approved medicines on this page: Scemblix and Imkeldi.
  • Gulf registers (checked 17 October 2026): see each medicine below.
  • Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
  • Price: Quote on request.

What is chronic myeloid leukemia (CML)?

Chronic myeloid leukemia (CML) is a disease in which the bone marrow makes too many white blood cells. It is a slowly progressing blood and bone marrow disease that usually occurs during or after middle age and rarely occurs in children.[1]

Most people with CML have a gene change called the Philadelphia (Ph) chromosome. Signs and symptoms include weight loss and tiredness, and blood and bone marrow tests are used to diagnose it.[1]

CML has three phases based on the share of immature blast cells in the blood and bone marrow: chronic phase, with fewer than 10%; accelerated phase, with 10% to 19%; and blastic phase, with 20% or more.[1]

Chronic myeloid leukemia (CML) in the Gulf

Gulf case reports and studies include a Saudi CML patient with a novel four-way translocation (2022) and a study of outcomes in pediatric CML with management focused on monitoring BCR-ABL transcript levels (2022).[2, 3]

We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 1 of 2 was listed in Saudi Arabia and 1 of 2 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[4, 5]

US FDA-approved medicines for chronic myeloid leukemia (CML)

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

  • Scemblix (asciminib)
    US FDA-approved for adults with Philadelphia chromosome-positive CML in chronic phase: newly diagnosed, previously treated, or with the T315I mutation. It is a tablet.[6]
    Current US label version: 22 September 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[4, 5]
    Country access guides: Saudi Arabia, UAE, Egypt, India, Pakistan
  • Imkeldi (imatinib oral solution)
    US FDA-approved for Philadelphia chromosome-positive CML in adults and children, including newly diagnosed chronic phase and other phases. It is an oral solution of imatinib, useful for patients who cannot swallow tablets.[7]
    Current US label version: 5 December 2024. Gulf registers: Saudi Arabia (SFDA drugs list): not found under this brand; products with the same active ingredient are listed (for example Cemivil, Glivec, Imalar). Abu Dhabi (DoH drug code list): not found under this brand; products with the same active ingredient are listed (for example Adalbern, Cemivil, Glivec). Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[4, 5]
    Country access guides: Saudi Arabia, UAE, Kuwait, Egypt, Lebanon, Turkey

How families in the Gulf can access treatment

If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[8, 9] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.

Who does what

  • Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
  • The hospital checks local supply, files any import request, and gives the treatment safely.
  • The national regulator decides whether to approve the import of a medicine that is not registered.
  • The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
  • Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

  • A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
  • Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
  • Recent clinic notes and a list of current medicines
  • For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
  • Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for chronic myeloid leukemia (CML)

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for chronic myeloid leukemia (CML)?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Scemblix and Imkeldi. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Scemblix available in Saudi Arabia or the UAE?

We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.

How can a family in the Gulf get Scemblix?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

Is imatinib already available in the Gulf?

Imatinib tablets are listed under several brand names in the Saudi and Abu Dhabi registers, as shown on this page. Imkeldi is a US-approved oral solution of imatinib, which is a different form.

Sources for the condition-specific answers: [4, 5, 7]

Sources

Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.

  1. National Cancer Institute (NCI): Chronic Myeloid Leukemia Treatment
  2. Dridi W, et al. Saudi Arabian CML patient with a novel four-way translocation at t(9;22;5;2)(q34;q11.2;p13;q44). Mol Genet Genomic Med. 2022 (PubMed 35543309)
  3. Al-Ghemlas I, et al. Outcome of pediatric chronic myeloid leukemia with management focusing on the monitoring of BCR-ABL fusion gene transcript levels. Int J Pediatr Adolesc Med. 2022 (PubMed 36090130)
  4. SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
  5. Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
  6. DailyMed: SCEMBLIX (asciminib) US prescribing information, label version 22 September 2026
  7. DailyMed: IMKELDI (imatinib oral solution) US prescribing information, label version 5 December 2024
  8. SFDA: Special Access Program (SAP) guidance, version 1.0
  9. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products

Related

This page is general health information, not medical advice. It does not replace a consultation with your doctor.

WhatsApp